2021 Revenues ($USD) : $17,813,600,000
2021 R&D spend : $751,100,000
2021 Number of Employees : 37,000
Fiscal Year End : 12/31/2021
Leader : CEO Michael Goettler

Created in 2020 as the merger of Mylan and Pfizer’s Upjohn unit, Viatris has a lineup of well-known off-patent drugs such as Viagra, Xanax and Lipitor — as well as other generics, over-the-counter drugs and active pharmaceutical ingredients. The company also had a variety of biosimilars, but is offloading them to Biocon Biologics in a transaction worth up to $3.34 billion. —BB